Akoya Biosciences, Inc. (AKYA)

Compare

1.3500

-0.0400

(-2.88%)

At close: April 1 at 4:00:01 PM EDT

1.3500

0.00

(0.00%)

After hours: April 1 at 4:20:00 PM EDT

Q4 2024 Quanterix Corp Earnings Call

Q4 2024 Quanterix Corp Earnings Call

Thomson Reuters StreetEvents 14 days ago

QTRX

AKYA
-2.88%
Quanterix Corp (QTRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges

Quanterix Corp (QTRX) reports an 11% revenue increase and improved margins, while navigating market volatility and strategic acquisitions.

GuruFocus.com 14 days ago

QTRX

AKYA
-2.88%
Akoya Biosciences (AKYA) Reports Q4 Loss, Lags Revenue Estimates

Akoya (AKYA) delivered earnings and revenue surprises of -13.33% and 1.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 15 days ago

AKYA
-2.88%
Akoya: Q4 Earnings Snapshot

MARLBOROUGH, Mass. AP) — Akoya Biosciences Inc. AKYA) on Monday reported a loss of $8.2 million in its fourth quarter.

Associated Press Finance 15 days ago

AKYA
-2.88%
Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2024. "Akoya navigated a challenging 2024 in the life science tools market, which was constrained by subdued capital equipment purchases, by successfully strengthening gross margins, reducing operating expenses and advancing our companion diagnostics programs throughout

GlobeNewswire 15 days ago

AKYA
-2.88%
QTRX
Quanterix Shareholder Opposes Proposed Akoya Biosciences Merger

Quanterix (QTRX) shareholder Kent Lake said Tuesday that it opposes the company's proposed deal with

PREMIUM
MT Newswires 21 days ago

QTRX

AKYA
-2.88%
Akoya Biosciences unveils strategic product roadmap

Akoya Biosciences (AKYA) announced its reagent product roadmap, featuring new ultrahigh-plex neurobiology panels for human and mouse applications. Building on the success of the Human IO60 and Mouse FFPE IO panels, which debuted at the Society for Immunotherapy of Cancer Annual Meeting in November 2024, this roadmap represents the next step in the company’s mission to provide cutting-edge tools for advancing research across multiple market including oncology, inflammatory disease and neurobiolog

TipRanks last month

AKYA
-2.88%
Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels

Rapid menu expansion with new high-plex human and mouse neurobiology panels joining the recently launched Human IO60 and Mouse FFPE IO Panels The new offerings solidify leadership in spatial biology and broaden reach to new verticals MARLBOROUGH, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, a spatial proteomics leader, announced its reagent product roadmap today, featuring new ultrahigh-plex neurobiology panels for human and mouse applications. Building on the success of the Human

GlobeNewswire last month

AKYA
-2.88%
Quanterix Agrees to Acquire Akoya Biosciences in All-Stock Deal

Quanterix (QTRX) and Akoya Biosciences (AKYA) said Friday they entered into a definitive merger agre

PREMIUM
MT Newswires 2 months ago

QTRX

AKYA
-2.88%
Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers

BILLERICA, Mass. and MARLBOROUGH, Mass., January 10, 2025--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ: AKYA), The Spatial Biology Company®, today announced a definitive merger agreement under which Quanterix will acquire Akoya in an all-stock transaction. The transaction will create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers.

Business Wire 2 months ago

AKYA
-2.88%
QTRX
Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma patients to better guide treatment decisions and potentially increase access to life saving therapies for those patients at high risk of developing metastatic diseaseMARLBOROUGH, Mass. and FRANKFURT, Germany, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology

GlobeNewswire 3 months ago

AKYA
-2.88%
Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone

MARLBOROUGH, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, announced that Nature Methods, one of the world’s leading scientific journals, has selected spatial proteomics as its prestigious “Method of the Year 2024”, recognizing the transformative potential of this approach in advancing biological research and medicine. As a global leader in spatial proteomics, with the industry’s largest installed base of 1300 instruments

GlobeNewswire 3 months ago

AKYA
-2.88%
Time To Worry? Analysts Just Downgraded Their Akoya Biosciences, Inc. (NASDAQ:AKYA) Outlook

Market forces rained on the parade of Akoya Biosciences, Inc. ( NASDAQ:AKYA ) shareholders today, when the analysts...

Simply Wall St. 4 months ago

AKYA
-2.88%
Akoya Biosciences Third Quarter 2024 Earnings: Misses Expectations

Akoya Biosciences ( NASDAQ:AKYA ) Third Quarter 2024 Results Key Financial Results Revenue: US$18.8m (down 25% from 3Q...

Simply Wall St. 4 months ago

AKYA
-2.88%
Akoya Biosciences Inc (AKYA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...

Despite a revenue decline, Akoya Biosciences Inc (AKYA) focuses on operational efficiencies and strategic partnerships to drive future growth.

GuruFocus.com 4 months ago

AKYA
-2.88%
Akoya Biosciences (AKYA) Reports Q3 Loss, Lags Revenue Estimates

Akoya (AKYA) delivered earnings and revenue surprises of 5.26% and 25.39%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 months ago

AKYA
-2.88%
BRBR
Akoya: Q3 Earnings Snapshot

AKYA) on Thursday reported a loss of $10.5 million in its third quarter. On a per-share basis, the Marlborough, Massachusetts-based company said it had a loss of 21 cents. Losses, adjusted for restructuring costs, were 18 cents per share.

Associated Press Finance 4 months ago

AKYA
-2.88%
Akoya Biosciences Reports Third Quarter 2024 Financial Results

MARLBOROUGH, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2024. “Our third-quarter results came in below expectations, largely due to ongoing capital equipment purchase constraints seen across the life science tools market. We remain optimistic about the long-term growth outlook of our industry, but we recognize the current environment will

GlobeNewswire 4 months ago

AKYA
-2.88%
Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel

Pre-orders now available; early access available for select strategic partners for the PhenoCode IO60 panel – The Fastest Ultrahigh-plex Panel for Immuno-Oncology Research Launches the Mouse FFPE IO panel, optimized for pre-clinical immuno-oncology applications to drive translational research insights Expands the PhenoCode catalog with barcodes that enable ultrahigh-plex, 100-biomarker experiments, making scalable spatial biology research accessible for every lab MARLBOROUGH, Mass., Nov. 05, 202

GlobeNewswire 4 months ago

AKYA
-2.88%
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024

MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least a d

GlobeNewswire 5 months ago

AKYA
-2.88%

Performance Overview

Return	AKYA	S&P 500 (^GSPC)
YTD	-41.05%	-4.23%
1-Year	-70.39%	+7.42%
3-Year	-87.55%	+23.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Akoya Biosciences, Inc. (AKYA)

Q4 2024 Quanterix Corp Earnings Call

Quanterix Corp (QTRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges

Akoya Biosciences (AKYA) Reports Q4 Loss, Lags Revenue Estimates

Akoya: Q4 Earnings Snapshot

Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

Quanterix Shareholder Opposes Proposed Akoya Biosciences Merger

Akoya Biosciences unveils strategic product roadmap

Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels

Quanterix Agrees to Acquire Akoya Biosciences in All-Stock Deal

Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers

Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone

Time To Worry? Analysts Just Downgraded Their Akoya Biosciences, Inc. (NASDAQ:AKYA) Outlook

Akoya Biosciences Third Quarter 2024 Earnings: Misses Expectations

Akoya Biosciences Inc (AKYA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...

Akoya Biosciences (AKYA) Reports Q3 Loss, Lags Revenue Estimates

Akoya: Q3 Earnings Snapshot

Akoya Biosciences Reports Third Quarter 2024 Financial Results

Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel

Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024

Performance Overview